Skip to main content

Szela Mary T's Form 4 filing

TriSalus Life Sciences, Inc.TLSI · filed Mar 20, 2026

Accession no.
0001628280-26-020186
Filed
Mar 20, 2026
Trade date
Mar 11-17, 2026
Filing delay
9 daysLate
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions. Open-market sales total $79.4K. It was filed 9 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Szela Mary TCIK 0001410289Director, Officer (CEO and President)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 11, 2026Common StockSSaleDisposed−4,358$4.13−$17,998.54768,931Direct
Mar 17, 2026Common StockSSaleDisposed−15,944$3.85−$61,384.4752,987Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)